UBS Group AG Purchases 130,922 Shares of NewAmsterdam Pharma Company N.V. $NAMS

UBS Group AG increased its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 17.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 899,442 shares of the company’s stock after purchasing an additional 130,922 shares during the period. UBS Group AG’s holdings in NewAmsterdam Pharma were worth $31,552,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Capital World Investors increased its holdings in NewAmsterdam Pharma by 17.1% in the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock valued at $279,358,000 after acquiring an additional 1,434,986 shares during the last quarter. Jennison Associates LLC increased its holdings in NewAmsterdam Pharma by 42.5% in the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after acquiring an additional 1,252,451 shares during the last quarter. Wellington Management Group LLP increased its holdings in NewAmsterdam Pharma by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock valued at $114,332,000 after acquiring an additional 697,129 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after acquiring an additional 1,062,359 shares during the last quarter. Finally, Polar Capital Holdings Plc increased its holdings in NewAmsterdam Pharma by 15.6% in the 3rd quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock valued at $82,807,000 after acquiring an additional 393,855 shares during the last quarter. 89.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Michael H. Davidson sold 443,707 shares of NewAmsterdam Pharma stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the completion of the transaction, the chief executive officer directly owned 174,144 shares of the company’s stock, valued at approximately $5,790,288. The trade was a 71.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Johannes Jacob Piete Kastelein sold 104,467 shares of NewAmsterdam Pharma stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $30.30, for a total transaction of $3,165,350.10. Following the transaction, the insider directly owned 69,302 shares of the company’s stock, valued at approximately $2,099,850.60. This represents a 60.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 1,168,286 shares of company stock valued at $38,211,967. Company insiders own 20.84% of the company’s stock.

NewAmsterdam Pharma Stock Up 11.1%

NewAmsterdam Pharma stock opened at $38.73 on Friday. The company’s 50-day moving average price is $31.77 and its 200-day moving average price is $34.24. NewAmsterdam Pharma Company N.V. has a twelve month low of $16.78 and a twelve month high of $42.00. The company has a market cap of $4.45 billion, a PE ratio of -21.64 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative return on equity of 25.90% and a negative net margin of 943.23%.The business had revenue of $3.04 million during the quarter. As a group, sell-side analysts expect that NewAmsterdam Pharma Company N.V. will post -1.89 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on NAMS. HC Wainwright upgraded shares of NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday. Cantor Fitzgerald reiterated an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Needham & Company LLC lifted their price target on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Finally, Guggenheim lifted their price target on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $48.00.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.